Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
Background: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retr...
- Autores:
-
Ruiz-Patinõ, Alejandro
Arrieta, Oscar
Cardona-Mendoza, Andrés Felipe
Martín, Claudio Marcelo
Raez, Luis Estuardo
Zatarain-Barrón, Zyanya Lucia
Barron, Feliciano
Ricaurte, Luisa María
Bravo-Garzón, María A.
Mas, Luis A.
Corrales, Luis
Rojas Puentes, Leonardo
Lupinacci, Lorena
Perazzo, Florencia
Bas, Carlos Arturo
Carranza, Omar E.
Puparelli, Carmen
Rizzo, Miguel M
Ruiz, Rossana
Rolfo, Christian
Archila, Pilar
Rodríguez, July F.
Vargas Báez, Carlos Alberto
Carranza, Hernán
Otero, Jorge Miguel
Pino, Luis Eduardo
Ortíz, Carlos
Laguado, Paola
Rosell, Rafael Costa
- Tipo de recurso:
- Fecha de publicación:
- 2020
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/2022
- Palabra clave:
- Estadificación de neoplasias
Sistema nervioso central
Estudios de cohortes
Adult
Immunotherapy
Lung neoplasms
- Rights
- License
- Attribution 4.0 International
Summary: | Background: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first-, second-, third- or fourth-line of immunotherapy was conducted. A matched comparison with a historical cohort of first-line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. Results: Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first-line was given to 39 patients (13.7%), second-line to 140 (48.8%), and as third-line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression-free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first-line (P < 0.001), type of response (P < 0.001) and PD-L1 status (P = 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (P = 0.05) but not PFS (P = 0.2). A total of 44 hyperprogressors were documented (19.8%, [95% CI 14.5–25.1%]). Leukocyte count over 5.300 cells/dL was present in both hyperprogressors and long-term responders. Conclusions: Patients who receive immune-checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment. |
---|